Rein Therapeutics Files 8-K
Ticker: RNTX · Form: 8-K · Filed: Aug 19, 2025 · CIK: 1420565
| Field | Detail |
|---|---|
| Company | Rein Therapeutics, Inc. (RNTX) |
| Form Type | 8-K |
| Filed Date | Aug 19, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, corporate-update, filing
TL;DR
Rein Therapeutics (formerly Aileron) filed an 8-K on Aug 19, 2025.
AI Summary
Rein Therapeutics, Inc. filed an 8-K on August 19, 2025, reporting other events and financial statements. The company, formerly known as Aileron Therapeutics, Inc. until March 29, 2024, is based in Austin, Texas.
Why It Matters
This filing indicates Rein Therapeutics is making official disclosures to the SEC, which could relate to significant corporate events or financial updates.
Risk Assessment
Risk Level: low — This is a routine SEC filing (8-K) that primarily reports on other events and financial statements, without immediate indication of significant financial distress or major strategic shifts.
Key Numbers
- 001-38130 — SEC File Number (Identifies the company's filing history with the SEC.)
- 13-4196017 — EIN (Employer Identification Number for tax purposes.)
Key Players & Entities
- Rein Therapeutics, Inc. (company) — Registrant
- Aileron Therapeutics, Inc. (company) — Former company name
- August 19, 2025 (date) — Date of earliest event reported
- Austin, Texas (location) — Principal executive offices
FAQ
What specific 'Other Events' are being reported in this 8-K filing?
The provided text does not detail the specific 'Other Events' beyond stating it is an item reported in the 8-K.
What is the significance of the company formerly being known as Aileron Therapeutics, Inc.?
The company underwent a name change from Aileron Therapeutics, Inc. to Rein Therapeutics, Inc. on March 29, 2024.
Where are Rein Therapeutics, Inc.'s principal executive offices located?
The principal executive offices are located at 12407 N. Mopac Expy., Suite 250, #390, Austin, Texas 78758.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is August 19, 2025.
What is the company's Standard Industrial Classification (SIC) code?
The company's SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 425 words · 2 min read · ~1 pages · Grade level 10.2 · Accepted 2025-08-19 08:06:45
Filing Documents
- d938122d8k.htm (8-K) — 23KB
- d938122dex991.htm (EX-99.1) — 9KB
- 0001193125-25-183073.txt ( ) — 149KB
- rntx-20250819.xsd (EX-101.SCH) — 3KB
- rntx-20250819_lab.xml (EX-101.LAB) — 18KB
- rntx-20250819_pre.xml (EX-101.PRE) — 11KB
- d938122d8k_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On August 19, 2025, Rein Therapeutics, Inc. issued a press release concerning the planned Phase 2 clinical trial of its LTI-03 product candidate in the U.K. A copy of the press release is attached as Exhibit 99.1 hereto. Item9.01 Financial Statements and Exhibits (d)Exhibits The following exhibits are filed with this report: Exhibit 99.1 The Company's press release dated August 19, 2025 Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REIN THERAPEUTICS, INC. Dated: August 19, 2025 /s/ Brian Windsor Brian Windsor, Ph.D., President and Chief Executive Officer